Prognostic and Predictive Insights From Genomic Assays for Breast Cancer in Diverse Populations: A Review.

Genomic assays are crucial for understanding the biological characteristics of tumors, providing valuable insights into prognosis and treatment response.

基因组检测对于理解肿瘤的生物学特性至关重要，为预后和治疗反应提供了宝贵的见解。

Their integration into personalized clinical decision-making has notably enhanced outcomes, making these assays particularly valuable for underrepresented populations, which often face disproportionately poorer prognoses.

它们的整合到个性化临床决策中显著提高了治疗结果，使得这些检测对于常常面临较差预后的代表性不足的人群特别有价值。

Expanding research to evaluate the performance and predictive value of these assays across diverse groups is essential to ensure equitable benefits for all patients.

扩大研究以评估这些检测在不同群体中的性能和预测价值是确保所有患者公平受益的必要条件。

observations

This review evaluated the distribution of risk estimates from multigene assays, primarily focusing on 21-, 70-, and 50-gene signature assays, their predictive capabilities and impact on breast cancer recurrence and survival outcomes across race and ethnicity groups.

本综述评估了多基因检测的风险估计分布，主要关注21、70和50基因标志物检测，它们的预测能力和对乳腺癌复发及生存结果的影响，以及这些影响在不同种族和民族群体中的差异。

Findings indicate that racial and ethnic disparities in breast cancer outcomes were influenced by a complex interplay of biological, social, and systemic factors.

研究结果表明，乳腺癌结果中的种族和民族差异受到生物学、社会和系统因素复杂相互作用的影响。

Black women were more likely to have aggressive tumor phenotypes, such as luminal B and basal-like subtypes, which contributed to poorer outcomes.

黑人女性更有可能出现侵袭性肿瘤表型，如 Luminal B 和基底样亚型，这导致了较差的临床结果。

These disparities persist even after adjusting for genomic assay results and molecular subtypes, suggesting that genomic factors alone cannot fully explain differences in clinical outcomes.

即使在调整了基因组检测结果和分子亚型后，这些差异仍然存在，这表明仅基因组因素无法完全解释临床结果的差异。

Although subgroup analyses from 2 randomized clinical trials showed no apparent differences in the 21-gene signature's predictive value across racial groups, further research is needed to ensure that genomic assays are equitably calibrated for diverse populations.

尽管两项随机临床试验的亚组分析显示，21基因签名在不同种族群体中的预测价值没有明显差异，但需要进一步的研究以确保基因组检测对于不同人群是公平校准的。

conclusions_and_relevance

This review supports genomic assays as valuable tools for informing prognosis and treatment decisions in breast cancer; however, they do not fully capture factors associated with racial and ethnic disparities in outcomes.

这项综述支持基因组检测作为告知乳腺癌预后和治疗决策的有价值工具；然而，它们并未完全捕捉到与种族和民族差异相关的预后因素。

A comprehensive approach that integrates genomic data with a deeper understanding of social determinants and systemic inequities is essential to ensure all patients benefit equitably from advancements in personalized medicine.

一种综合方法，将基因组数据与对社会决定因素和系统性不平等更深入的理解相结合，对于确保所有患者都能公平地从个性化医学的进步中受益至关重要。